GST disruption, pricing pressure, and strong structural headwinds one-off charge in US dents quarter for SUNP
Edelweiss reports gZetia contributed USD55mn to earnings; base business erosion high
It is not just the Trump effect that Indian Pharma industry has to grapple with; it has to face the GST test too
Edelweiss reports the commercial vehicle lender has been operationally strong and merger uncertainties prevail
Report suggests that drug-manufacturer’s R&D investments have offset its gross margins with demanding valuations
Palghar is drawing swarms of investors looking to grab a piece of picturesque land
Company FDs look attractive with the higher returns but they are fraught with loopholes.